Ads
related to: psoriasis injection treatment skyrim release- Clinical Studies
Review Clinical Trial Results for
a Plaque Psoriasis Treatment.
- Safety & Risk Factor Info
View Metabolic Syndrome Risk Info
For a Psoriasis Treatment Option.
- Real-World Data for HCPs
Review Real-World Study Results
For a Psoriasis Treatment Option.
- Important HCP Information
See Psoriasis Treatment Options To
Help Your Patients Find Relief.
- Find Resources For HCPs
Learn About Services To Help
Patients Start And Stay On Therapy.
- Safety & Prescribing Info
View Safety & Prescription Info for
a Plaque Psoriasis Treatment.
- Clinical Studies
Search results
Results From The WOW.Com Content Network
Risankizumab, sold under the brand name Skyrizi (/ s k aɪ ˈ r ɪ z i / sky-RIZZ-ee), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. [6] [7] It is designed to target interleukin 23A (IL-23A). [6] [7] [9] It is given by subcutaneous injection. [6] [7]
Tildrakizumab, sold under the brand name Ilumya among others, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. [4] It is approved for the treatment of adults with moderate-to-severe plaque psoriasis in the United States and in the European Union. [2] [3] [5]
Spesolimab, sold under the brand name Spevigo, is a monoclonal antibody used for the treatment of generalized pustular psoriasis (GPP). [4] It is an interleukin-36 receptor (IL-36R) antagonist. [ 4 ] [ 6 ] It is given via injection into a vein.
Guselkumab lowers the release of immune system signalling molecules, increasing the risk of infections from bacteria, viruses, and fungi. [7]The most common side effects for guselkumab are upper respiratory tract infections, headache, injection site reactions, [10] joint pain, diarrhea, gastroenteritis, fungal skin infections and herpes simplex infections.
Ustekinumab is used to treat psoriasis. [29] This includes psoriatic arthritis when it affects the skin. [31] [29] It is indicated for the treatment of adult and adolescent patients (12 years and older) with moderate to severe plaque psoriasis (Ps) who are candidates for phototherapy or systemic therapy, and adults with active psoriatic arthritis (PsA) alone or in combination with methotrexate.
Secukinumab inhibits a member of the cytokine family, interleukin 17A, which is produced mainly by inflammatory T helper 17 cells. [11] IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in ...
Ads
related to: psoriasis injection treatment skyrim release